Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Need for innovative treatments for HL: Creating a benchmark

Paul Jan Bröckelmann • 15 Jun 2019
EHA 2019
Hodgkin Lymphoma Lymphoma

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, discusses a recent publication on the outcomes of patients with third or higher relapsed classical Hodgkin lymphoma from the German Hodgkin Study Group at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. The study Dr Bröckelmann mentions has allowed for the development of a benchmark for Hodgkin lymphoma and will help a patient group in need of innovative agents.

More from Paul Jan Bröckelmann

2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals